|
**Overview**: **Organic Acids Quantitative Profile****Introduction**: The Organic Acids Quantitative Profile is a diagnostic tool designed to screen for metabolic disorders using urine samples. Associated with conditions like organic acidemias and mitochondrial disorders, these disorders present with developmental delay, vomiting, and severe complications if untreated, particularly in individuals with suspected metabolic issues. Per the 2023 Biochemistry and Clinical Pathology guidelines, the test employs biochemistry and clinical pathology with HPLC-MS/MS technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for metabolic screening in clinical settings. This diagnostic falls under metabolic screening and targets individuals with suspected metabolic disorders, addressing the challenge of accurate organic acid assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its urine-based approach ensures reliable detection.**Other Names**: Org Acids Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry and clinical pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1980s by metabolic labs, this test advanced organic acid analysis.**Purpose**: The test screens for 132 parameters including lactic acid to guide metabolic assessment, assess organic acid profiles, and inform treatment and prevention strategies.**Test Parameters**: 1. Lactic Acid, 2. Pyruvic Acid, 3. Methylmalonic Acid, 4. 3-Hydroxybutyric Acid, 5. Acetoacetic Acid, 6. Glutaric Acid, 7. 3-Hydroxyglutaric Acid, 8. 2-Hydroxyglutaric Acid, 9. Propionic Acid, 10. Isovaleric Acid, 11. Methylcitric Acid, 12. Homogentisic Acid, 13. Succinic Acid, 14â€"132. Other organic acids (e.g., fatty acid metabolites, amino acid derivatives, and related compounds).**Pretest Condition**: No fasting required; patients should report developmental delay, vomiting, or recent metabolic symptoms.**Specimen**: 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on developmental delay, vomiting, prior metabolic reactions, or family history of metabolic disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated metabolic disorders including brain damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using HPLC-MS/MS and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent dietary changes can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible metabolic disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.**Specialist Consultation**: General practitioners or specialists in metabolic disorders should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Urine organic acid analysis or enzyme assays for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry and Clinical Pathology Guidelines 2023, Journal of Metabolic Diseases 2024, Chemistry 2025. |
